EconPapers    
Economics at your fingertips  
 

Targeting Cancer by siRNA; A Review on Current Strategies

Muhammad Irfan and Iqra Rashid
Additional contact information
Iqra Rashid: Department of Biochemistry and Biotechnology,University of Gujrat,Pakistan

JOJ Sciences, 2018, vol. 1, issue 5, 104-112

Abstract: Recent development in RNA Interference (RNAi) brought enthusiasm in the scientific community and opened the new ways for many therapeutic applications. The RNAi is a phenomenon which is used to targets mRNA and chops them up. The most appealing work of RNAi is observed in cancer inhibition by silencing genome sequences. Ultimate level of specificity can be achieved through siRNA targeted therapeutics. Short interfering RNA(siRNA) belongs to dsRNA molecules that can be produced exogenously and endogenously. This review sums up the recent approaches for cancer inhibition by siRNA. The article also points out the current targets of siRNA in cancer therapy development including expression level of cancerous and non-cancerous cells, their genetic concerns and siRNA drug delivery system like lipid base Nano-vectors. Currently, many of RNA based drugs are in practice at clinical trials level to overcome this deadly disease. In view of the encouraging results of RNAi based therapy, it is obvious that in near future siRNA will prove itself as a major cancer inhibitor and can become a standard cancer treatment.

Keywords: JOJ Sciences; joj sciences impact factor; joj material science; molecular biology; juniper publishers: contemporary life science research; genetics; microbiology; neurobiology; plant biology; structural biology and virology; juniper publishers; open access; high impact journals list; high impact journals; scholarly open access journals; peer reivewed journals; junipe publishers review; Targeting cancer; siRNA; Nucleic acids; Drug treatments; Silencing; Nucleotides; Endogenously; Exogenously; dsRNA; Transfection; Electroporation; DNA; mRNA; Nucleases; Molecular level; Immune system; Glomeruli; Urine; serum proteins; Polycaprolactane (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/jojs/pdf/JOJS.MS.ID.555573.pdf (application/pdf)
https://juniperpublishers.com/jojs/JOJS.MS.ID.555573.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:oajojs:v:1:y:2018:i:5:p:104-112

DOI: 10.19080/JOJS.2018.01.555573

Access Statistics for this article

JOJ Sciences is currently edited by Sophia Mathis

More articles in JOJ Sciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().

 
Page updated 2025-03-19
Handle: RePEc:adp:oajojs:v:1:y:2018:i:5:p:104-112